New lung cancer treatment kept a hard-to-treat tumor type in check far longer

Lung cancer is a hard topic to read about with your coffee. Here is some good news. A new first treatment for one hard-to-treat form of advanced lung cancer kept the disease from growing for far longer than the usual treatment did. And it caused fewer severe side effects.

You can’t change a diagnosis from your kitchen table. But you can know that progress is happening for people who need it, and that it is real. It could matter for someone you love.

How the study worked

Researchers followed 455 adults with advanced nonsquamous non-small-cell lung cancer that had not been treated yet. Their tumors had very little of a protein called PD-L1 and no mutations that a drug could target. A computer assigned each person by chance to one of two groups. One group got a newer drug called sacituzumab tirumotecan plus the immunotherapy pembrolizumab (229 people). The other got standard chemotherapy plus pembrolizumab (226 people). Independent reviewers who did not know which treatment each person got judged whether the cancer had grown. The results are from a planned midpoint check, after a median follow-up of 9.7 months, in a trial funded by the drugmaker, and they were published Oct. 25, 2026, in the New England Journal of Medicine.

What they found

The cancer stayed in check much longer with the new combination. People on it went a median of 15.0 months without their cancer growing. People on the standard combination went a median of 5.7 months. In plain terms, that is about 15 months versus about 6.

The new treatment also made the good effect last. Tumors shrank in about half of the people in both groups. But when tumors shrank on the new combination, the benefit held for a median of 13.6 months. On the standard combination, it held for 6.8 months.

Severe side effects (grade 3 or higher) were less common with the new combination. Mouth sores were common with it, but most were mild or moderate.

The researchers also looked at how long people lived. Those numbers are still early, since the trial is ongoing. They point in favor of the new combination, and the team will keep following everyone.

What is PD-L1, and why does it matter?

Pembrolizumab is an immunotherapy. It helps your immune system spot and attack cancer. It tends to work best when tumors make a lot of a protein called PD-L1. When a tumor makes almost none, as in this trial, doctors have usually paired immunotherapy with chemotherapy. Results with that pairing have left room for improvement.

The new drug works differently from plain chemotherapy. It is an antibody-drug conjugate. It finds a protein on cancer cells called TROP2 and delivers chemotherapy right to them. That is why researchers hoped it could do more for these tumors.

What you can do today

If you or someone close to you is facing advanced lung cancer, take two minutes to write down two questions for the oncologist. First, what was the PD-L1 result on the tumor? Second, was the tumor tested for targetable mutations? Those two answers help the care team choose the right first treatment, and they open the door to asking about newer combinations and clinical trials. Bring the page to the next appointment.